



# KOVAI MEDICAL CENTER AND HOSPITAL LIMITED

NABH Accredited Hospital

Excellence in Healthcare

99, Avanashi Road, Coimbatore - 641 014. INDIA | Phone : (0422) 4323800, 4324000, 6803000

Web : www.kmchhospitals.com | CIN No : L85110TZ1985PLC001659



29.05.2024

Ref: KMCH/SEC/SE/2023-24/2151

To

Corporate Relationship Department  
BSE Limited 1 st Floor,  
New Trading Ring Rotunda Building,  
P.J.Towers Dalal Street, Fort  
Mumbai - 400 001

Dear Sirs,

## **Sub: Outcome of the Board Meeting.**

This is to inform you that the Board of directors at their meeting held on 29<sup>th</sup> May 2024, had inter alia considered and approved the following:

### **1. Audited financial results for the quarter and financial year ended 31<sup>st</sup> March 2024.**

Audited Standalone Financial Results of the Company for the financial year ended 31<sup>st</sup> March 2024.

Auditors Report on the Financial Results of the company for the year ended 31<sup>st</sup> March 2024. As regards the Audited Financial Results of the company, it is hereby declared that the Auditors have given an Un-modified opinion in their report.

### **2. Recommendation of dividend**

Recommended a final dividend of 100% on the equity capital (Rs.10/- per share) of the company for the Financial Year ended 31<sup>st</sup> March 2024 subject to the approval of shareholders at the ensuing Annual General Meeting. We also wish to inform you that the Board has fixed the record date as Friday, the 2<sup>nd</sup> August 2024 for the purpose of determining the entitlement of dividend for the financial year ended March 31, 2024.

### **3. Reappointment of Dr.Nalla G Palaniswami as Managing Director of the Company**

Approved the Re-appointment of Dr.Nalla G Palaniswami (00013536) as Managing Director of the Company for a period of five years w.e.f. 01.10.2024, subject to the approval of shareholders.

### **4. Proposal to appoint Mr.Vasanth Kumar Venkatasamy(DIN: 00217764) as Independent Director of the Company**

The Board of Directors on recommendation of Nomination and Remuneration Committee, Proposed the Appointment of Mr.Vasanth Kumar Venkatasamy(DIN: 00217764) as an Independent Director of the Company for a period of 5 Years with effect from 01.09.2024, subject to the approval of shareholders.





**5. Recommendation to reappoint Mrs.V.Bhuvaneshwari(DIN:01628512) as Independent Director of the Company**

The Board of Directors, on Recommendation of Nomination and Remuneration Committee, recommended the Reappointment of Mrs.V.Bhuvaneshwari (DIN: 01628512) as an Independent Director for a second term of Five Years with effect from 3<sup>rd</sup> September 2024, subject to the approval of Shareholders at the ensuing Annual General Meeting.

**6. Annual General Meeting and Book Closure**

1.To convene the 38<sup>th</sup> Annual General Meeting of the Company on Wednesday, 14<sup>th</sup> August 2024.

2.To close the Register of Members & Share Transfer Books of the Company from Friday, 2<sup>nd</sup> August 2024 to Wednesday, 14<sup>th</sup> August 2024 (both days inclusive) for the purpose of payment of dividend and AGM.

3.The cut-off date for determining eligibility of shareholders for e-voting / voting in AGM is on Friday, 2<sup>nd</sup> August 2024.

**7. Re-appointment of Cost Auditor**

The Board of Directors has re-appointed Mr.V.Sakthivel, Cost Accountant, (Membership No.23292) Cost Accountant, M/s RKMS & Associates, as Cost Auditor of the Company for the audit of the Cost Records for the financial year 2024-25.

**8. Re-appointment of Secretarial Auditor**

The Board of Directors has re-appointed M/s KSR & Co Company Secretaries LLP, as Secretarial Auditor of the Company to conduct the Secretarial Audit for the financial year 2024-25.

**9. Re-appointment of Internal Auditor**

The Board of Directors has re-appointed Mr.G.Jawaharlal, Chartered Accountant, Salem, as Internal Auditor of the Company for the financial year 2024-25.

The details as required under SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed hereunder as 'Annexure I'





**KOVAI MEDICAL CENTER AND HOSPITAL LIMITED**

Excellence in Healthcare

Coimbatore - 641 014. | CIN No : L85110TZ1985PLC001659

Continuation Sheet No. 2

The Board meeting commenced at 4.23 PM and concluded at 5.57 PM


You are requested to kindly take note of the same.

Yours truly,

For Kovai Medical Center and Hospital Limited

R. Ponmanikandan  
Company Secretary



**Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015:****Annexure - I - Re-appointment of Directors:**

Details of Events that need to be provided	Information on Such Events	Information on Such Events	Information on Such Events
Name	Dr.Nalla G Palaniswami	Mr. Vasanth Kumar Venkatasamy	Mrs.V.Bhuvaneshwari
Reasons for Change VIZ. appointment, resignation, removal, death or otherwis	Reappointment as Managing Director	Proposed to appoint as Independent Director with effect from 01.09.2024	Reappointment as Independent Director for the Second Term.
Date of Appointment	Dr. Nalla G Palaniswami is recommended for Reappointment as Managing Director of the Company, for a further period of five years effective 01.10.2024, subject to shareholders approval. His present tenure as Executive Director will conclude on 30.09.2024.	-	Mrs.V.Bhuvaneshwari is recommended to reappoint as the Independent Director of the Company with effect from 3 <sup>rd</sup> September 2024. Her present tenure ends on 2 <sup>nd</sup> September 2024.
Brief profile	Over 50 Years of Experience. Was practicing Medicine in USA for more than 15 years when he decided to return to India to set up KMCH. Since 01 Oct 1989 he has been been the Managing Director of KMCH steering the Company to its present state.	He is a Post Graduate in Business Administration at Leonard N. stern school of Business, USA. He has got extensive professional Expertise in Corporate Finance and Business Operations.	Seasoned Advocate with expertise in Corporate Law.Experienced in Joint Ventures, Mergers and Acquisitions, Collaborations and technology transfers.
Disclosure of relationships between Directors	Wife: Dr. Thavamani Devi Palaniswami Son: Dr.Mohan S Gounder and Dr. Arun N Palaniswami Daughter: Dr. Purani P Palaniswami	NIL	NIL
Shareholding if any, in the Company	10,000 Equity Shares	NIL	NIL





KOVAI MEDICAL CENTER AND HOSPITAL LIMITED  
Corporate Identification Number (CIN) : L85110TZ1985PLC001659  
Registered Office : 99, Avanashi Road, Coimbatore - 641 014  
Phone: (0422) 4323800, 3083800, Fax : (0422) - 2627782

E-mail: secretarialdept@kmchhospitals.com, Website : www.kmchhospitals.com

Statement of Audited Financial Results for the Quarter/ Year Ended 31st March 2024

(₹ in lakhs)

S. No	Particulars	Quarter Ended			Year Ended	Year Ended
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		(Unaudited)			(Audited)	(Audited)
1	<b>Income</b>					
	a) Revenue from Operations	32,078.57	32,078.54	26,668.30	1,21,827.07	1,01,856.09
	b) Other Operating Income	32.61	32.23	30.45	128.20	118.59
	c) Other Income	564.61	486.58	523.28	2,094.92	1,598.77
	<b>Total Income</b>	<b>32,675.79</b>	<b>32,597.35</b>	<b>27,222.03</b>	<b>1,24,050.19</b>	<b>1,03,573.45</b>
2	<b>Expenses</b>					
	a) Cost of Medicines & Hospital consumables consumed	8,467.14	8,387.72	7,471.52	32,389.87	28,284.31
	b) Employee benefits expense	5,683.79	5,653.14	5,028.89	21,946.54	17,969.70
	c) Finance Costs	688.85	734.35	996.42	3,294.39	4,015.61
	d) Consulting Charges to Doctors	4,548.26	4,460.93	3,856.83	17,574.88	15,160.43
	e) Depreciation and amortization expenses	2,351.72	2,334.50	2,168.10	9,213.62	8,912.50
	f) Other Expenses	4,245.48	3,975.23	3,632.98	15,875.22	13,708.91
	<b>Total Expenses</b>	<b>25,985.24</b>	<b>25,545.87</b>	<b>23,154.74</b>	<b>1,00,294.52</b>	<b>88,051.46</b>
3	<b>Profit before Tax (1-2)</b>	<b>6,690.55</b>	<b>7,051.48</b>	<b>4,067.29</b>	<b>23,755.67</b>	<b>15,521.99</b>
4	<b>Tax expense</b>					
	a) Current Tax	1,354.42	1,715.23	918.56	5,633.10	3,918.00
	b) Taxation for earlier years	(112.42)	2.80	(2.81)	(65.65)	(106.98)
	c) Deferred Tax	230.84	23.70	95.83	215.15	134.36
	<b>Total Tax Expenses</b>	<b>1,472.84</b>	<b>1,741.73</b>	<b>1,011.58</b>	<b>5,782.60</b>	<b>3,945.38</b>
5	<b>Profit for the period from continuing operations (3-4)</b>	<b>5,217.71</b>	<b>5,309.75</b>	<b>3,055.71</b>	<b>17,973.07</b>	<b>11,576.61</b>
6	<b>OTHER COMPREHENSIVE INCOME</b>					
	<b>A) Items that will not be reclassified to profit or loss</b>					
	Remeasurement of post employment benefit obligations	23.06	171.41	67.63	75.36	67.90
	Change in equity instruments measured at FVOCI	9.14	3.66	(3.21)	18.95	3.57
	<b>B) Income Tax relating to above items</b>	<b>(8.11)</b>	<b>17.16</b>	<b>(16.22)</b>	<b>(23.74)</b>	<b>(17.99)</b>
	<b>Total Other Comprehensive Income</b>	<b>24.09</b>	<b>192.23</b>	<b>48.20</b>	<b>70.57</b>	<b>53.48</b>
7	<b>Total Comprehensive Income For The Period (5+6)</b>	<b>5,241.80</b>	<b>5,501.98</b>	<b>3,103.91</b>	<b>18,043.64</b>	<b>11,630.09</b>
8	<b>Basic and diluted Earnings Per Share</b>	<b>47.68</b>	<b>48.52</b>	<b>27.93</b>	<b>164.25</b>	<b>105.80</b>



*Handwritten signature*

Statement of Assets and Liabilities

Particulars	31.03.2024	31.03.2023
	(Audited)	(Audited)
<b>ASSETS</b>		
<b>1. Non Current Assets</b>		
(a) Property, plant & equipment	1,08,790.74	1,05,413.34
(b) Right of use assets	2,829.11	3,181.19
(c) Capital work in progress	3,863.10	2,332.38
(d) Intangible assets	148.34	160.10
(e) Financial assets		
(i) Investments	45.35	26.40
(ii) Other financial assets	1,498.53	2,752.24
(f) Other non-current assets	1,606.81	441.21
<b>Total Non Current Assets</b>	<b>1,18,781.98</b>	<b>1,14,306.86</b>
<b>2. Current Assets</b>		
(a) Inventories	1,469.85	1,372.40
(b) Financial Assets		
(i) Trade receivables	1,680.54	2,135.12
(ii) Cash & cash equivalents	5,960.21	1,795.19
(iii) Bank balances other than cash & cash equivalents	15,145.66	23,063.82
(iv) Others financial assets	337.74	569.71
(c) Other current assets	447.42	569.21
<b>Total Current Assets</b>	<b>25,041.42</b>	<b>29,505.45</b>
<b>TOTAL - ASSETS</b>	<b>1,43,823.40</b>	<b>1,43,812.31</b>
<b>EQUITY AND LIABILITIES</b>		
<b>1. Equity</b>		
(a) Equity Share Capital	1,094.23	1,094.23
(b) Other Equity	87,759.62	70,810.20
<b>Total Equity</b>	<b>88,853.85</b>	<b>71,904.43</b>
<b>2. Non Current Liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	25,318.08	44,736.75
(ii) Lease liabilities	3,334.74	3,571.26
(iii) Other financial liabilities	45.78	42.69
(b) Provisions	2,020.95	1,880.59
(c) Deferred tax liabilities (net)	3,789.41	3,550.53
(d) Other non-current liabilities	6.50	9.85
<b>Total Non Current Liabilities</b>	<b>34,515.46</b>	<b>53,791.67</b>
<b>3. Current Liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	2,122.01	2,562.32
(ii) Lease liabilities	260.77	220.94
(iii) Trade payables		
a) Dues to Micro & Small Enterprises	188.06	78.95
b) Dues to Others	2,451.37	2,654.45
(iv) Other financial liabilities	8,825.27	5,887.89
(b) Other current liabilities	5,995.67	6,126.33
(c) Provisions	610.94	582.02
(d) Current tax liabilities	-	3.31
<b>Total Current Liabilities</b>	<b>20,454.09</b>	<b>18,116.21</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,43,823.40</b>	<b>1,43,812.31</b>



Segment wise Revenue, Results and Capital Employed

(₹ in lakhs)

Particulars	Quarter Ended 31.03.2024	Quarter Ended 31.12.2023	Quarter Ended 31.03.2023	Year Ended 31.03.2024	Year Ended 31.03.2023
	(Unaudited)			Audited	Audited
<b>Segment Revenue</b>					
Healthcare	29,046.77	29,486.09	24,690.66	1,12,589.36	95,262.69
Education	3,064.41	2,624.68	2,008.09	9,365.91	6,711.99
Sub-total	32,111.18	32,110.77	26,698.75	1,21,955.27	1,01,974.68
Less : Inter-segment revenue	-	-	-	-	-
<b>Revenue from Operations</b>	<b>32,111.18</b>	<b>32,110.77</b>	<b>26,698.75</b>	<b>1,21,955.27</b>	<b>1,01,974.68</b>
<b>Segment Results</b>					
Profit/(loss) before interest and tax					
Healthcare	6,229.70	6,971.79	4,876.48	24,794.78	18,641.91
Education	1,673.83	1,364.14	733.80	4,480.18	2,415.65
Sub-total	7,903.53	8,335.93	5,610.28	29,274.96	21,057.56
Add: Unallocated Income	-	3.92	-	17.70	51.06
Less : Finance Cost	688.85	734.35	996.42	3,294.39	4,015.61
Unallocated expenses	524.13	554.02	546.57	2,242.60	1,571.02
<b>Profit before tax (PBT)</b>	<b>6,690.55</b>	<b>7,051.48</b>	<b>4,067.29</b>	<b>23,755.67</b>	<b>15,521.99</b>
<b>Capital employed</b>					
(Segment assets - Segment liabilities)					
(a) Healthcare					
Segment assets	1,04,538.80	1,09,124.63	1,10,489.85	1,04,538.80	1,10,489.85
Segment liabilities	(36,380.57)	(38,505.57)	(49,380.73)	(36,380.57)	(49,380.74)
(b) Education					
Segment assets	32,642.05	27,327.32	29,928.02	32,642.05	29,928.02
Segment liabilities	(13,305.82)	(15,161.82)	(17,893.19)	(13,305.82)	(17,893.19)
(c) Unallocated					
Assets	6,642.55	5,560.84	3,394.44	6,642.55	3,394.44
Liabilities	(5,283.16)	(4,733.31)	(4,633.96)	(5,283.16)	(4,633.96)
<b>Total</b>	<b>88,853.85</b>	<b>83,612.09</b>	<b>71,904.43</b>	<b>88,853.85</b>	<b>71,904.43</b>



*DR. NALLA G PALANISWAMI*

DR. NALLA G PALANISWAMI  
MANAGING DIRECTOR  
DIN : 00013536

COIMBATORE  
29.05.2024

Notes :

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board at its meeting held on 29th of May 2024.
- 2 The Board of Directors recommended a final dividend of Rs. 10 per Equity share (of face value of Rs.10/- each) for the year 2023-24, subject to the approval of the shareholders in Annual General Meeting.
- 3 The Company has reported segment information as per Indian Accounting Standards 108 - "Operating Segments" (Ind AS 108).
- 4 The figures for the quarter ended 31st March 2024 and 31st March 2023 are the balancing figures between audited figures in respect of the full financial year and the year to date figures up to the third quarter of the respective financial years, which were subject to limited review by the Statutory auditors.
- 5 Figures of the previous period / year have been regrouped / re-arranged wherever necessary to conform to the current period / year presentation.



COIMBATORE  
29.05.2024

  
DR.NALLA G PALANISWAMI  
MANAGING DIRECTOR  
DIN : 00013536





## STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 31ST MARCH 2024

(₹ in lakhs)

Particulars	31st March 2024 (Audited)		31st March 2023 (Audited)	
<b>A. CASH FLOW FROM OPERATING ACTIVITIES:</b>				
Profit before taxation and exceptional items		23,755.67		15,521.99
Adjustment for:				
Depreciation and amortisation expense	9,213.62		8,912.50	
Exchange fluctuation loss/(gain) - (net)	0.16		(1.32)	
Finance cost	3,276.08		4,000.54	
Dividend Income	(0.73)		(0.40)	
Non Cash transactions	(185.82)		25.59	
Loss/(profit) on Sale of Property,Plant & equipment (net)	(4.50)		(3.56)	
		12,298.81		12,933.35
<b>Operating cash flow before working capital changes</b>		<b>36,054.48</b>		<b>28,455.34</b>
(Increase) / Decrease in non current & current financial assets	1,835.89		(2,341.17)	
(Increase) / Decrease in other non current & current assets	121.78		(233.36)	
Increase / (Decrease) in non current & current financial liabilities	1,948.45		2,565.58	
(Decrease) / Increase in other non current & current liabilities	164.07		1,574.43	
		4,070.19		1,565.48
<b>Cash generated from operations</b>		<b>40,124.67</b>		<b>30,020.82</b>
Income Tax paid		(5,711.41)		(3,729.60)
<b>Net cash generated from operating activities (A)</b>		<b>34,413.26</b>		<b>26,291.22</b>
<b>B. CASH FLOW FROM/ (USED IN) INVESTING ACTIVITIES:</b>				
Purchase of Property, Plant & Equipment, CWIP & intangible assets	(13,842.26)		(12,739.58)	
Proceeds relating to Property, Plant & Equipment	24.30		55.86	
Investment in Equity Instruments	-		(2.53)	
Dividend Income	0.73		0.40	
<b>Net cash from / (used in) investing activities (B)</b>		<b>(13,817.23)</b>		<b>(12,685.85)</b>
<b>C. CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES:</b>				
Long term Borrowings (Net off Repayment)	(19,849.91)		(2,832.33)	
Short term Borrowings (Net)	(9.07)		(997.57)	
Repayment of lease liabilities	(539.64)		(429.84)	
Finance Cost paid	(2,860.16)		(3,652.65)	
Dividend Paid	(1,090.39)		(657.90)	
<b>Net cash from / (used in) financing activities (C)</b>		<b>(24,349.17)</b>		<b>(8,570.29)</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>		<b>(3,753.14)</b>		<b>5,035.08</b>
Cash and cash equivalents at the beginning of the period		24,859.01		19,823.93
Less: Bank Balances not considered as Cash & Cash equivalents as per Ind AS 7		15,145.66		23,063.82
<b>Cash and Cash equivalent at the end of the period</b>		<b>5,960.21</b>		<b>1,795.19</b>



**Independent Auditor's Report on Annual Financial Results**

**To the Board of Directors**

**Kovai Medical Center and Hospital Limited**

**Opinion**

1. We have audited the accompanying Annual Financial Results ("the Statement") of Kovai Medical Center and Hospital Limited ("the company") for the year ended 31<sup>st</sup> March, 2024, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
  - ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India, of the net profit (after tax), other comprehensive income and other financial information of the company for the year ended 31<sup>st</sup> March, 2024.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of Annual Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

**Management's and Board of Directors Responsibilities for the Annual Financial Results**

4. This Statement has been prepared on the basis of the Annual Financial Statements and has been approved by the Company's Board of Directors. The Company's Management and Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit, other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read



with relevant rules issued thereunder, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

5. In preparing the Statement, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of Annual Financial Results**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls;



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors;
  - Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

11. This Statement includes the Financial Results for the quarter ended 31<sup>st</sup> March 2024 and quarter ended 31<sup>st</sup> March 2023, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of those financial years, which were subjected to limited review by us.

For VKS Aiyer & Co  
Chartered Accountants  
ICAI Firm Registration No.000066S



*C S Sathyanarayanan*  
C S Sathyanarayanan  
Partner  
Membership No. 028328  
UDIN: 24028328BKGSVS5850

Place: Coimbatore  
Date : 29-05-2024



# KOVAI MEDICAL CENTER AND HOSPITAL LIMITED

NABH Accredited Hospital

Excellence in Healthcare

99, Avanashi Road, Coimbatore - 641 014. INDIA | Phone : (0422) 4323800, 4324000, 6803000

Web : www.kmchhospitals.com | CIN No : L85110TZ1985PLC001659



29.05.2024

Ref: KMCH/SEC/SE/2024-25/

To

Corporate Relationship Department  
BSE Limited  
1<sup>st</sup> Floor, New Trading Ring Rotunda Building,  
P.J.Towers Dalal Street, Fort  
Mumbai - 400 001.

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).


In terms of the provisions of Regulation 33(3)(d) of Listing Regulations, as amended and Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016, we confirm that the Independent Auditors of the Company, M/s VKS Aiyer & Co., Chartered Accountants (FRN: 000066S) have issued an Audit Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the quarter and year ended on 31st March, 2024.

You are requested to take the same on record.

Thanking You,

Yours Truly

For Kovai Medical Center and Hospital Limited

  
P.K. Gopikrishnan  
Chief Financial Officer





# KOVAI MEDICAL CENTER AND HOSPITAL LIMITED

NABH Accredited Hospital

Excellence in Healthcare

99, Avanashi Road, Coimbatore - 641 014. INDIA | Phone : (0422) 4323800, 4324000, 6803000

Web : www.kmchhospitals.com | CIN No : L85110TZ1985PLC001659



29.05.2024

Ref: KMCH/SEC/SE/2024-25/

To

Corporate Relationship Department  
BSE Limited  
1st Floor, New Trading Ring  
Rotunda Building, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001

Dear Sirs,

Sub: Submission of details with regards to Large Corporate for the Financial Year ended March 31, 2024.

Pursuant to SEBI Circular No. SEBI/HO/DDHS/DDHSRACPODI/P/CIR/2023/172 dated October 19, 2023, and emails received from BSE Limited, we hereby confirm that the Company does not fall under the criteria as specified at para 2.2 of the aforesaid SEBI Circular for the Financial Year ended 31<sup>st</sup> March 2024.

S.NO	Particulars	Details
1	Outstanding Qualified Borrowings at the start of the financial year (In Crores)	0.00
2	Outstanding Qualified Borrowings at the end of the financial year (In Crores)	0.00
3	Highest credit rating of the company relating to the unsupported bank borrowings or plain vanilla bonds, which have no structuring/support Built in.	A1+*
4	Incremental borrowing done during the year (qualified borrowing) (In Crores)	0.00
5	Borrowings by way of issuance of debt securities during the year (In Crores)	0.00

\*- Short-term Bank Facilities (Secured)

Kindly take the same on record.

For Kovai Medical Center and Hospital Limited

P.K.Gopikrishnan  
Chief Financial Officer

